title: Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure.
abstract: A common polymorphism exists for the aldosterone synthase (CYP11B2) gene at position 344 (C-344-T). The 344-C allele has been associated with increased aldosterone synthase activity. We hypothesized that the aldosterone synthase gene polymorphism is associated with adverse cardiac remodeling in an ambulatory, chronic heart failure population. The CYP11B2 C-344T genotype was determined in 104 patients with heart failure who were in New York Heart Association classes I to IV, had left ventricular ejection fractions <40%, and were prospectively recruited from an urban heart failure clinic (65% African-American, 69% had a nonischemic cause, with a mean left ventricular ejection fraction of 22 +/- 9%). The 344-C allele frequency was 0.34 (45.2% TT, 42.3% CT, and 12.5% CC) and was significantly lower in African-American (0.27) versus Non-African-American patients (0.44, p = 0.018). Baseline and 1-year follow-up echocardiograms were obtained in 74 patients. Improvement was defined as a decrease in left ventricular end-systolic diameter (LVESD). At follow-up, the 344-C allele was associated with improved LVESD (p = 0.013). In addition, analysis by race showed that this effect was observed only in African-American patients (p <0.006). In multivariate logistic regression, controlling for cause, gender, and spironolactone use, the TT genotype (i.e., absence of 344-C allele) was associated with a fivefold lower rate of improvement in LVESD in African-Americans (p = 0.014). In conclusion, the 344-C allele of the aldosterone synthase gene polymorphism was associated with improved cardiac remodeling over time for African-Americans with chronic systolic heart failure. Although this genetic-driven increase in aldosterone activity should predispose to worse cardiac remodeling, it may represent a more susceptible state and enhanced response to therapy in this racial subgroup.
authors.affiliation: Cardiovascular Section and Evans Department of Medicine, Boston University School of Public Health, Boston, Massachusetts, USA.
authors.forename: Andreia
authors.initials: A
authors.lastname: Biolo
authors.forename: Tania
authors.initials: T
authors.lastname: Chao
authors.forename: Toni-Ann S
authors.initials: TA
authors.lastname: Duhaney
authors.forename: Eugene
authors.initials: E
authors.lastname: Kotlyar
authors.forename: Donald
authors.initials: D
authors.lastname: Allensworth-Davies
authors.forename: Joseph
authors.initials: J
authors.lastname: Loscalzo
authors.forename: Flora
authors.initials: F
authors.lastname: Sam
mesh_terms: D001741:Black or African American / Q000235:genetics*; D000450:Aldosterone / Q000502:physiology; D000483:Alleles; D002908:Chronic Disease; D019405:Cytochrome P-450 CYP11B2 / Q000235:genetics*; D004452:Echocardiography; D005260:Female; D006333:Heart Failure / Q000235:genetics / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D013318:Stroke Volume; D020257:Ventricular Remodeling
chemical_list: D000450:Aldosterone; D019405:Cytochrome P-450 CYP11B2